Skip to NavigationSkip to content

Allergan launches Crestor generic in the US

Published on 03/05/16 at 08:37am

Allergan has received FDA approval on the generic version of AstraZeneca’s high cholesterol drug, Crestor (rosuvastatin), and has become the first company to launch a generic of the drug in the US.

Crestor has consistently been one of the highest selling in the drugs in the US, but went off patent earlier this year. It is a member of the drug class of statins, used with a combination of lifestyle factors to treat high cholesterol and related conditions, as well prevent cardiovascular disease.

According to data from IMS Health, Crestor generated sales of $6.5 billion, in the US alone, for the 12 months to March 31 2016.

Allergan has launched its generic version of Crestor according to an agreement struck with AstraZeneca on March 25 2013, and 67 days prior to the expiration of paediatric exclusivity in July.

Robert Stewart, executive VP of generics and global operations at Allergan, says: “This first-to-market launch demonstrates the talent of our generics team in developing, manufacturing and bringing to market high-quality, affordable versions of widely used medicines like Crestor. This is expected to be the largest generic launch in 2016, benefitting patients and reducing cost for US health systems.”

Sean Murray

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches